Company: CDT
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001641172-25-023191
Chunk: 13

Company: CDT Equity Inc.
Filing Date: 2025-08-12
Form: 424B3
Chunk 13
---
 and/or the development of other clinical assets;                                           |
| ● | the                                                                                                                                
 costs of operating as a public company;                                                                                            |
| ● | the                                                                                                                                
 time and cost necessary to respond to technological and market developments;                                                       |
| ● | any                                                                                                                                
 disputes which may occur between us, employees, collaborators, or other prospective business partners; and                         |
| ● | the                                                                                                                                
 costs of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights.                   |

If we raise additional funds by selling shares of our Common Stock or other equity-linked securities, the ownership interest of our current stockholders will be diluted. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, or clinical assets or to grant licenses on terms that may not be acceptable to us. If we raise additional funds through debt financing, we may have to grant, if able, a security interest on our assets to the future lenders, our debt service costs may be substantial, and any current or future lenders may have a preferential position in connection with any future bankruptcy or liquidation involving the Company.

On August 6, 2025, the last quoted sale price for our Common Stock as reported on Nasdaq was $1.86 per share. Currently, the exercise prices of the Company’s warrants are far greater than the current market price of our Common Stock. Accordingly, such warrants are unlikely to be exercised and therefore the Company does not expect to receive any proceeds from such exercise of the warrants in the near term. Whether any holders of warrants determine to exercise such warrants, which would result in cash proceeds to the Company, will likely depend upon the market price of our Common Stock at the time of any such holder’s determination.

If we are unable to raise additional capital when needed, we may be required to curtail the development of our technology or materially curtail or reduce our operations. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms could have a material adverse effect on our business, results of operations, and financial condition, including the possibility that a lack of funds could cause our business to fail and our Company to dissolve and liquidate with little or no return to investors.

<div align